| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2008 | US20080182906 Therapy for diabetic retinopathy |
| 07/31/2008 | US20080182905 Using (4,5,6,7-tetrahydro-5,5,8,8-tetramethylnaphthalen-2-yl)carbamoyl benzoic acid |
| 07/31/2008 | US20080182904 Antidepressants; psychological disorders |
| 07/31/2008 | US20080182903 Weight control; sexual disorders; stomach blotting; gastrointestinal disorders; anticholesterol agents |
| 07/31/2008 | US20080182902 Sphingolipids in Treatment and Prevention of Steatosis and of Steatosis or of Hepatotoxicity and its Sequelae |
| 07/31/2008 | US20080182901 Crystalline acid of lipoxin A4 analogs and method of making |
| 07/31/2008 | US20080182900 Method of treatment of virus infections using shikonin compounds |
| 07/31/2008 | US20080182899 Adrenergic receptor antagonist and enzyme inhibitors; antidepressant; anxiolytic agents |
| 07/31/2008 | US20080182898 Treatment of metabolic syndrome with norfluoxetine |
| 07/31/2008 | US20080182897 Crystalline potassium salt of lipoxin A4 analogs |
| 07/31/2008 | US20080182896 Use of metal chelates in human or animal feeding |
| 07/31/2008 | US20080182895 Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| 07/31/2008 | US20080182894 Efficiency; determine , calibration nutrients needed for therapy |
| 07/31/2008 | US20080182893 Prevention, therapy atherosclerosis; prevent plaque destabilization; using ienzyme modified soquercitrin |
| 07/31/2008 | US20080182892 Treatment of interstitial cystitis using (6aR, 10aR)-delta-8-tetrahydrocannabinol-11-oic acids |
| 07/31/2008 | US20080182891 Chromane and chromene derivatives and uses thereof |
| 07/31/2008 | US20080182890 Methods of using low-dose doxepin for the improvement of sleep |
| 07/31/2008 | US20080182889 Prodrugs of excitatory amino acids |
| 07/31/2008 | US20080182888 Novel Crystalline Compounds |
| 07/31/2008 | US20080182887 atorvastatin, atorvastatin lactone less than 0.5% by weight of atorvastatin, and carrier comprising 0.5% - 3.0% by weight of tromethamine and an additional stabilizer (antioxident) to prevent degradation of atorvastatin; storage stability |
| 07/31/2008 | US20080182885 Modified Azole Compounds As Antifungal and Antibacterial Agents |
| 07/31/2008 | US20080182883 e.g. 1-Benzyl-3-pentyl-2-[6-(1H-tetraazol-5-ylmethoxy)-2-naphthyl]-1H-indole; stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 07/31/2008 | US20080182882 E.g., N-(5-chloro-2-methylbenzyl)-N'-hydroxy-4-(hydroxymethyl)-1,2,5-oxadiazole-3-carboximidamide; inhibiting immunosuppression; treating cancer, viral infection, depression, neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or autoimmune disease |
| 07/31/2008 | US20080182881 TNF-alpha production inhibitors |
| 07/31/2008 | US20080182880 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-]thiazolidinedione; physical form of pioglitazone; sulfonylureas, metformin, or the alpha -glucosidase inhibitors, peroxisome proliferator-activated receptor-gamma agonist; antidiabetic, hypoglycemic agent; insulin resistance |
| 07/31/2008 | US20080182879 e.g. 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone; tyrosine kinase inhibitors, anticarcinogenic and antiinflammatory agent; cerebral, genito-urinary tract, lymphatic system, stomach, laryngeal, pancreatic, breast or lung tumor; rheumatoid arthritis, psoriasis, contact dermatitis |
| 07/31/2008 | US20080182878 benzothienyl containing amido-derivatives, antibacterial agent; quorum sensing regulated virulence factors; inhibiting biofilm formation; virulence gene expression blocking agent, disinfectants, antifouling coatings |
| 07/31/2008 | US20080182877 Rimonabant forms and methods of making the same |
| 07/31/2008 | US20080182876 Histamine H3-Receptor Ligands and Their Therapeutic Application |
| 07/31/2008 | US20080182875 N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide |
| 07/31/2008 | US20080182874 e.g. 1-[6-Chloro-5-[(tricyclo[3.3.1.13,7]dec-1-ylacetyl)amino]-2-quinolinyl]-4piperidinecarboxylic acid; adamantyl-containing purinergic receptor P2X7 antagonists; antiinflammatory agent, immune or cardiovascular diseases; asthma, chronic obstructive pulmonary disease, rheumatoid arthritis |
| 07/31/2008 | US20080182873 Process for the manufacture of hmg-coa reductase inhibitors |
| 07/31/2008 | US20080182872 e.g. 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol or 3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile; estrogen receptor beta selective modulator; antiinflammatory agent; induced by peritonitis or intravenous bacteremia during sepsis, or by oxygen toxicity; |
| 07/31/2008 | US20080182871 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. |
| 07/31/2008 | US20080182870 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
| 07/31/2008 | US20080182868 Novel chemical compounds |
| 07/31/2008 | US20080182867 Administering one or more rapamycin derivatives (including rapamycin and 40-O-(2-hydroxy)ethyl-rapamycin); lymphocytic leukemia, lymphoma, Epstein-Barr virus, inhibiting graft rejection and metastasis; drug screening |
| 07/31/2008 | US20080182866 Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis |
| 07/31/2008 | US20080182865 combination of at least one selective histone deacetylase inhibitor and kinase inhibitor with anti-EGFR activity (gefitinib, erlotinib, lapatinib, sutent, vandetanib, or sorafenib); anticarcinogenic agent; non-small cell lung, breast, skin, bladder, colon, prostate, uterine, cervical, ovarian cancer |
| 07/31/2008 | US20080182864 2-(1-Aroylaminoalkyl)-3-(alkylaryl)-7-(halo- or cyano)quinazolinone derivatives, e.g., 2-[1'-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin-4-one; mitotic kinesin spindle protein inhibitors; disrupting mitosis; modulating mitotic spindle formation; restenosis |
| 07/31/2008 | US20080182863 e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers |
| 07/31/2008 | US20080182862 e.g. 1-(isoquinolin-1-yl)-N3-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1H-1,2,4-triazole-3,5-diamine; protein tyrosine kinase receptor Axl inhibitor; bioassay; antiinflammatory, anticarcinogenic agent, anticoagulant; rheumatoid arthritis, vascular disease, diabetic retinopathy, osteoporosis |
| 07/31/2008 | US20080182861 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| 07/31/2008 | US20080182860 Pyrimidine Compounds as Purine Receptor Antagonist |
| 07/31/2008 | US20080182859 Small organic molecule regulators of cell proliferation |
| 07/31/2008 | US20080182858 infectious disorders; antiarrhythmic, antifibrillatory agents; 1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride; different polymorphic, hydrate and solvate forms of compound are advantageous for the manufacture of compositions |
| 07/31/2008 | US20080182857 Heat Shock Protein 90 inhibitors; 5-(2,4-dihydroxyphenyl)-4-(naphth-1-yl)-4H-1,2,4-triazole-3-thiol; incorrect protein folding or aggregation; hydrazonederivatives react with dimiadazole cabonyl/thiocarbonyl derivatives; hydrazines derivatives react with isocyanate or isothiocyanates; tumors, cancer |
| 07/31/2008 | US20080182856 Novel crystalline forms of aripiprazole |
| 07/31/2008 | US20080182855 Antibacterial Quinoline Derivatives |
| 07/31/2008 | US20080182854 4-Amino-5-Cyanopyrimidine Derivatives |
| 07/31/2008 | US20080182853 suppressing neuronal death; sudden loss of oxygen and/or energy loss, and degenerative diseases, such as Alzheimer's disease; Parkinson's disease; ischemic states |
| 07/31/2008 | US20080182852 Anthranilamide inhibitors of aurora kinase |
| 07/31/2008 | US20080182851 Acetylene derivatives as stearoyl coa desaturase inhibitors |
| 07/31/2008 | US20080182850 3-(heteroaryl)alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 |
| 07/31/2008 | US20080182849 Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds |
| 07/31/2008 | US20080182848 anxiety; insomnia; high yielding; optically resolving eszopiclone using a multi-column continuous process or a simulated moving bed process; stationary phase used in chiral chromatography process is a derivative of tris(3,5-dimethylphenyl carbamate), or a derivative of tris- alpha -methylbenzylcarbamate |
| 07/31/2008 | US20080182847 Anticancer agents; potent Deoxycytidine kinase inhibitors; inhibit thymidine kinase; inhibit uridine kinase; N-[3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-3-bromo-benzenesulfonamide |
| 07/31/2008 | US20080182846 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound |
| 07/31/2008 | US20080182845 Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| 07/31/2008 | US20080182844 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof |
| 07/31/2008 | US20080182843 Mitotic Kinesin Inhibitors |
| 07/31/2008 | US20080182842 L-alanine derivatives as a5beta1 antagonists |
| 07/31/2008 | US20080182841 Sustained release bioadhesive carrier such as polycarbophil; coronary antiarrhythmic; local anesthetic; calcium channel blocker; autocoid; antiprostaglandin; nonsteroidal antiinflammatory; cyclooxygenase, thromboxane or leukotriene inhibitor; infertility |
| 07/31/2008 | US20080182840 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one |
| 07/31/2008 | US20080182839 LFA1 related immune and/or inflammatory disorders; interactions with leukointegrins; such as fused nitrogen heterocyclic secondary amine derivatives |
| 07/31/2008 | US20080182838 (5-{5-[4-(2-Bromo-5-fluorophenoxy)piperidin-1-yl]pyrazin-2-yl}-2H-tetrazol-2-yl)acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL |
| 07/31/2008 | US20080182837 New chemical compounds |
| 07/31/2008 | US20080182836 Cephalosporin compounds comprising a C3 thio-methyl moiety substituted with N-containing heterocyclic group, and a C7 thiourea acetamido group, their preparations and uses thereof |
| 07/31/2008 | US20080182835 Cobalt attached/coordinated to 6 same or different ligands including a N-based ligand donor atom that is ammonia, primary amine or secondary amine, or salt; does not have free cobalt(III) coordination sites and does not hydrolyze oligonucleotides; complex may be bound to an oligonucleotide |
| 07/31/2008 | US20080182834 less toxic than the unassociated metal complex by hindering reactions in the blood stream; antitumor agents; platinum, palladium, gold amine inclusion compounds |
| 07/31/2008 | US20080182832 orphan nuclear Receptor agonists; chenodeoxycholic acid, ursodeoxycholic acid or cholic acid derivatives; atherosclerosis, arteriosclerosis, dyslipidemia, hypercholesterolemia, and hypertriglyceridemia.atherosclerosis, arteriosclerosis, hypercholestremia, and hyperlipidemia |
| 07/31/2008 | US20080182831 e.g. Cyanomethyl (6 alpha ,11 beta ,16 alpha ,17 alpha )-17-({[(1,1-dimethylethyl)oxy]carbonyl}oxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylate; glucocorticoid receptor agonists of the androstane series; with other beta 2-adrenoreceptor agonist; asthma, rhinitis, eczema |
| 07/31/2008 | US20080182830 Agent for Treatment and Prevention of Endometriosis and Uterine Adenomyosis |
| 07/31/2008 | US20080182829 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens |
| 07/31/2008 | US20080182828 dominant estrogenic activity phase of three daily doses of an estrogen equivalent to 1 mg per day of 17 beta -estradiol per day and a dominant progestagenic activity phase of a combination of an estrogen and a progestogen equivalent to 90 mu g per day of norgestimate; hot flushes |
| 07/31/2008 | US20080182827 mixture of sustained release oral minocycline hydrochloride (tetracyclin) antibiotic, and fast dissolving carrier, and slow dissolving carrier (encapsulates said intragranular fast dissolving carrier) at ratio of about 0.3 to 0.5; dosage form comprises a coating; once-a-day dosing regimen |
| 07/31/2008 | US20080182826 Method for the treatment of acne |
| 07/31/2008 | US20080182825 oral dosage form antiacne agent containing minocycline antibiotic; lactose monohydrate as fast dissolving carrier; e.g. polyvinyl pyrrolidone, hydroxypropylmethyl cellulose as slow dissolving carrier; fewer side effects; sustained release |
| 07/31/2008 | US20080182824 e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance |
| 07/31/2008 | US20080182823 E.g., polyethylene glycol-linked alendronate or pamidronate; osteoporosis, osteopenia, urolithiasis, hypercalcemia, Paget's disease, bone metastasis, multiple myeloma, or neoplastic bone lesion |
| 07/31/2008 | US20080182822 Liquid Pharmaceutical Compositions Comprising a Bisphosphonate Compound |
| 07/31/2008 | US20080182821 Anti-Inflammatory and/or Analgesic Composition For the Intestine Comprising Branched Maltodextrins |
| 07/31/2008 | US20080182820 Mixtures of sulfated oligosaccharides |
| 07/31/2008 | US20080182819 Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders |
| 07/31/2008 | US20080182818 Th1 CELL DIFFERENTIATION ACCELERATOR |
| 07/31/2008 | US20080182817 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| 07/31/2008 | US20080182816 Utilizing prodrug technique to couple polysaccharides containing galactose with a parent compound through different bridge linkage to derive conjugates; polysaccharide component protects 5-fluorouracil(5-FU) from absorption in the upper gastrointestinal tract, delivers the 5-FU to colorectal area |
| 07/31/2008 | US20080182815 Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) |
| 07/31/2008 | US20080182814 Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
| 07/31/2008 | US20080182813 UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING |
| 07/31/2008 | US20080182812 Disease model animals of metabolic syndrome and a method of screening preventive and therapeutic agents for metabolic syndrome using the same |
| 07/31/2008 | US20080182811 Activating a metabotropic glutamate receptor by administering one or more kinds of amino acids selected from amino acids other than glutamic acid; use in treating neurological diseases, cardiovascular diseases, surgical diseases, neurosurgical diseases, thoracic surgical diseases, orthopedic diseases |
| 07/31/2008 | US20080182810 Antisense modulation of acyl coa cholesterol acyltransferase-2 expression |
| 07/31/2008 | US20080182809 Oligonucleotide sequences which bind biomolecules such as peptides, hydrophobic molecules and extracellular proteins for diagnosing and treating cardiovascular disorders in mammals |
| 07/31/2008 | US20080182808 Capable of inducing breakdown of mrna enzymes that break down connective tissue; particularly suited for treating degenerative skin disorders; pharmaceutical and cosmetic compositions for topical application and which contain the oligoribonucleotides |
| 07/31/2008 | US20080182807 gene therapy against tumors and cancer; expression vector includes insert into tumor an effective amount of polynucleotides encoding a functionally active p53, express p53 to first DNA damaging agent, contact tumor cell with first DNA damaging agent, and kill tumor cell |
| 07/31/2008 | US20080182806 Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
| 07/31/2008 | US20080182805 O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-Acetyl moiety |
| 07/31/2008 | US20080182804 Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines |
| 07/31/2008 | US20080182803 extract from Cassia or Senna plants comprises rubrofusarin gentiobioside with egg white, egg membrane, milk whey, yeast/vegetable proteins, soy bean, L-cysteine, L-methionine, and vitamin C; synergistic; intracellular biosynthesis of glutathione stimulator; liver, brain, vision, or immune disorders |